The future of best practice

Atherosclerosis

Volumn 143, Issue SUPPL. 1, 1999, Pages

  Kastelein, J J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Coronary heart disease; Pathogenesis; Western world

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN B; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DRUG COST; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

ANTILIPEMIC AGENTS; CARDIOLOGY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERCHOLESTEROLEMIA; MYOCARDIAL REVASCULARIZATION;

EID: 0033011117     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00103-3     Document Type: Conference Paper

References (31)

1. World Health Report. Report of the Director General. WHO, Geneva, 1998.
2. Kannel WB, Dawber TR, Kagan Aet al. Factors of risk in the development of coronary heart disease: six-year follow-up experience. Ann Int Med. 55:1961;33-50.
3. Doyle JT, Dawber TR, Kannel WBet al. Cigarette smoking and coronary heart disease: combined experience of the Albany and Framingham studies. N Engl J Med. 266:1962;796-801.
4. Pasternak RC, Grundy SM, Levy Det al. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol. 27:1996;978-990.
5. Turner RC, Millns H, Neil HAWet al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J. 316:1998;823-828.
6. Murray CJ, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet. 349:1997;1498-1504.
7. Fact Book Fiscal Year 1997. Bethesda MD: National Heart, Lung, and Blood Institute, 1997.
8. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 2:1986;933-936.
9. Verschuren WM, Jacobs DR, Bloemberg BPet al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. J Am Med Assoc. 274:1995;131-136.
10. Chen Z, Peto R, Collins Ret al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Br Med J. 303:1991;276-282.
11. Wakugami K, Iseki K, Kimura Yet al. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J. 62:1998;7-14.
12. Holme I Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 76:1995;10C-17C.
13. Roussouw JE Lipid-lowering interventions in angiographic trials. Am J Cardiol. 76:1995;86C-92C.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994:344(8934);1383-1389.
15. Shepherd J, Cobbe SM, Ford Iet al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
16. Sacks FM, Pfeffer MA, Moye LAet al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 335:1996;1001-1009.
17. Downs JR, Clearfield M, Weis Set al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc. 279:1998;1615-1622.
18. Pedersen TR, Olsson AG, Faergeman Oet al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
19. Pyorala K, Steiner G Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence. Ann Med. 28:1996;357-362.
20. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 15:1992;820-825.
21. Pyorala K, Pedersen TR, Kjekshus Jet al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
22. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the AVERT Investigators. Effects of lipid lowering with atorvastatin on cardiovascular ischemic events: results of the Atorvastatin Versus Revascularization Treatments (AVERT) study. N Engl J Med 1999; in press.
23. Jones P, Kafonek S, Laurora I, Hunninghake D Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol. 81:1998;582-587.
24. Boden WE, O'Rourke RA, Crawford MHet al. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 338:1998;1785-1792.
25. Schwartz GG, Oliver MF, Ezekowitz MDet al. Rationale and design of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 81:1998;578-581.
26. Sacks FM, Moyé LA, Davis BRet al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation. 97:1998;1446-1452.
27. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997:336;153-162.
28. Davidson M, McKenney J, Stein Eet al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 79:1997;1475-1481.
29. Bertolini S, Bon GB, Campbell LMet al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 130:1997;191-197.
30. Dart A, Jerums G, Nicholson Get al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 80:1997;39-44.
31. Amsterdam EA, Hyson D, Kappagoda CT Nonpharmacologic therapy for coronary artery atherosclerosis: results of primary and secondary prevention trials. Am Heart J. 128:1994;1344-1352.